By Melissa Lipman ( November 19, 2013, 5:11 PM EST) -- The Federal Trade Commission told a Pennsylvania federal court Monday that the launch of generic versions of Cephalon Inc.'s Provigil did not moot its pay-for-delay suit against the drugmaker, because it can still pursue the billions of dollars Cephalon made while the deals were in place....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.